search
Back to results

Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer

Primary Purpose

Advanced Primary Liver Cancer

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Elemene
Sponsored by
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Primary Liver Cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-75 years old,No limit on gender
  • Patients who are confirmed Locally advanced or metastatic primary liver cancer in accordance with the clinical diagnostic criteria , or by pathological histology or cytology examination, Patients who are unable to accept surgery,radiofrequency ablation、TACE and local therapy ,orLocal treatment progress failed
  • didn't have any systematic treatment including systematic chemotherapy and molecular targeted therapy
  • According to RECIST V1.1,1at least has one measurable lesions
  • ECOG Score ≤1
  • Patients who have primary liver cancer with Child - Pugh liver function grade rating A or better B(score<=7)
  • Laboratory inspection basically meets the following requirements:Blood test:a. Hb>=90g/L(without blood transfusion within 14 days), b. ANC>=1.5×10^9/L, c. PLT>=80×10^9/L. Biochemical test:a. ALB>=28g/L(without blood transfusion within 14 days), b. ALT and AST <=5ULN, c. TBIL<=2ULN, d. Cr<=1.5ULN.Blood Coagulation function: PT<=ULN+6seconds
  • Life expectancy of at least 3 months
  • Subjects join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up

Exclusion Criteria:

  • Patients have a adjuvant therapy using Oxaliplatin within 6 months
  • Patients have other anti-cancer treatment , including α-IFN,Arsenious Acid Injection and other Traditional Chinese Medicine Patent Prescription for treating cancer
  • Patients blood pressure need to be controled(Systolic blood pressure>150mmHg , Diastolic blood pressure>90mmHg), Congestive heart failure , Unstable angina pectoris , New angina pectoris , and have no Myocardial infarction within 6months
  • Patients with severe acute infection and cann't be controled , Chronic suppurative infection , body temperature>=39℃ , Pleural effusion(medium and large) combined with infection
  • Patients with central nervous system metastasis and has symptoms
  • In the past or at the same time,patients were diagnosed with other malignant tumor which have not been cured. As for skin basal cell carcinoma and cervical carcinoma in situ,they can be excepted
  • Women who is pregnant or during breast feeding and not willing to contraception during the test
  • Coagulation dysfunction(PT>16 seconds , APTT>43 seconds , TT>21 seconds , Fib<2g/L) , With bleeding tendency or the presence of vital organ thrombosis (lung, brain) is receiving thrombolytic or anticoagulant therapy
  • With a mental illness, or has a history of drugs abuse
  • Patients accepted any experimental drugs in the past 4 weeks
  • Other reasons the researchers think not suitable

Sites / Locations

  • 302 Military Hospital of China
  • The First Hospital of Lanzhou University
  • The First Hospital of Hebei Medical UniversityRecruiting
  • Harbin Medical University Cancer Hospital
  • Henan Medical University Cancer Hospital
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Xiehe University of Science and Technology Affiliate Tongji Hospital
  • Jinan Military General Hospital
  • The Affiliated Hospital of Qindao University
  • Shanghai Oriental Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Elemene +Oxaliplatin

Oxaliplatin

Arm Description

the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin

the group treated with Systematic Chemotherapy including Oxaliplatin

Outcomes

Primary Outcome Measures

Objective response rate and/or 1-year survival rate
Objective response rate.The proportion of patients who had a best response rating of complete response and partial response.

Secondary Outcome Measures

Disease control rate(DCR)
Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease.
Progression-free survival(PFS)
Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause
Overall survival(OS)
Overall survival.The time of patient from randomization to death caused by any cause
Quality of Life Questionnaire (QLQ)
Quality of Life Questionnaire Core 30
the rate of incidence of adverse events
NCI CTC AE 4.03

Full Information

First Posted
May 22, 2017
Last Updated
May 23, 2017
Sponsor
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Collaborators
Dalian Holley Kingkong Pharmaceutical Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03166553
Brief Title
Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer
Official Title
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination With Systematic Chemotherapy Including Oxaliplatin in the First -Line Treatment of Advanced Primary Liver Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 28, 2016 (Actual)
Primary Completion Date
May 28, 2019 (Anticipated)
Study Completion Date
November 27, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Collaborators
Dalian Holley Kingkong Pharmaceutical Co., Ltd

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer
Detailed Description
Patients with advanced primary liver cancer will be enrolled in the trial , then separated randomly into two group. One group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin , another group treated with Systematic Chemotherapy including Oxaliplatin. The purpose of the study is to evaluate the effect and safety of the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Primary Liver Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
One group treated with the Elemene Injection/Elemene Oral Emulusion in Combination with Systematic Chemotherapy including Oxaliplatin , another group treated with Systematic Chemotherapy including Oxaliplatin.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Elemene +Oxaliplatin
Arm Type
Experimental
Arm Description
the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
Arm Title
Oxaliplatin
Arm Type
No Intervention
Arm Description
the group treated with Systematic Chemotherapy including Oxaliplatin
Intervention Type
Drug
Intervention Name(s)
Elemene
Other Intervention Name(s)
Oxaliplatin
Primary Outcome Measure Information:
Title
Objective response rate and/or 1-year survival rate
Description
Objective response rate.The proportion of patients who had a best response rating of complete response and partial response.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Disease control rate(DCR)
Description
Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease.
Time Frame
1 year
Title
Progression-free survival(PFS)
Description
Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause
Time Frame
1 year
Title
Overall survival(OS)
Description
Overall survival.The time of patient from randomization to death caused by any cause
Time Frame
3 year
Title
Quality of Life Questionnaire (QLQ)
Description
Quality of Life Questionnaire Core 30
Time Frame
3 year
Title
the rate of incidence of adverse events
Description
NCI CTC AE 4.03
Time Frame
3 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-75 years old,No limit on gender Patients who are confirmed Locally advanced or metastatic primary liver cancer in accordance with the clinical diagnostic criteria , or by pathological histology or cytology examination, Patients who are unable to accept surgery,radiofrequency ablation、TACE and local therapy ,orLocal treatment progress failed didn't have any systematic treatment including systematic chemotherapy and molecular targeted therapy According to RECIST V1.1,1at least has one measurable lesions ECOG Score ≤1 Patients who have primary liver cancer with Child - Pugh liver function grade rating A or better B(score<=7) Laboratory inspection basically meets the following requirements:Blood test:a. Hb>=90g/L(without blood transfusion within 14 days), b. ANC>=1.5×10^9/L, c. PLT>=80×10^9/L. Biochemical test:a. ALB>=28g/L(without blood transfusion within 14 days), b. ALT and AST <=5ULN, c. TBIL<=2ULN, d. Cr<=1.5ULN.Blood Coagulation function: PT<=ULN+6seconds Life expectancy of at least 3 months Subjects join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up Exclusion Criteria: Patients have a adjuvant therapy using Oxaliplatin within 6 months Patients have other anti-cancer treatment , including α-IFN,Arsenious Acid Injection and other Traditional Chinese Medicine Patent Prescription for treating cancer Patients blood pressure need to be controled(Systolic blood pressure>150mmHg , Diastolic blood pressure>90mmHg), Congestive heart failure , Unstable angina pectoris , New angina pectoris , and have no Myocardial infarction within 6months Patients with severe acute infection and cann't be controled , Chronic suppurative infection , body temperature>=39℃ , Pleural effusion(medium and large) combined with infection Patients with central nervous system metastasis and has symptoms In the past or at the same time,patients were diagnosed with other malignant tumor which have not been cured. As for skin basal cell carcinoma and cervical carcinoma in situ,they can be excepted Women who is pregnant or during breast feeding and not willing to contraception during the test Coagulation dysfunction(PT>16 seconds , APTT>43 seconds , TT>21 seconds , Fib<2g/L) , With bleeding tendency or the presence of vital organ thrombosis (lung, brain) is receiving thrombolytic or anticoagulant therapy With a mental illness, or has a history of drugs abuse Patients accepted any experimental drugs in the past 4 weeks Other reasons the researchers think not suitable
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shukui Qin
Phone
025-80864541
Email
qinsk@csco.org.cn
Facility Information:
Facility Name
302 Military Hospital of China
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100039
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yinying Lu
Facility Name
The First Hospital of Lanzhou University
City
Lanzhou
State/Province
Gansu
ZIP/Postal Code
730000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Da Zhao
Facility Name
The First Hospital of Hebei Medical University
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yonghui An
Facility Name
Harbin Medical University Cancer Hospital
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuxian Bai
Facility Name
Henan Medical University Cancer Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huaimin Liu
Facility Name
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xianglin Yuan
Facility Name
Xiehe University of Science and Technology Affiliate Tongji Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
43000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tao Zhang
Facility Name
Jinan Military General Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Baochen Wang
Facility Name
The Affiliated Hospital of Qindao University
City
Qindao
State/Province
Shandong
ZIP/Postal Code
266000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wensheng Qiu
Facility Name
Shanghai Oriental Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200000
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jin Li

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer

We'll reach out to this number within 24 hrs